This poster is published under an
open license. Please read the
disclaimer for further details.
Keywords:
Contrast agents, Kidney, CT, Audit and standards, Contrast agent-intravenous, Safety, Toxicity
Authors:
L. H. Cope1, D. Howlett2, K. Drinkwater3; 1Tyne and Wear/UK, 2Eastbourne/UK, 3London/UK
DOI:
10.1594/ecr2017/C-1655
Conclusion
Compliance with guidance on CI-AKI is poor.
Therefore,
departments do not have assurance that the risk of CI-AKI in UK CT practice is minimized,
or that CI-AKI is detected and managed appropriately in high risk patients.
To inform the decision to prescribe IV contrast the radiologist requires recent kidney function tests as the risk of developing CI-AKI increases with increasing levels of chronic kidney disease.
18% Outpatient scans in a concurrent audit of UK contrast enhanced CT were pre-booked follow up scans where kidney function at the time of making the request will be outside the recommended time limit when the scan is performed.
Developing a policy for management of patients in whom CI-AKI is detected following a scan requires collaboration between radiology departments,
acute care physicians and renal physicians.
Having a policy ensures consistent patient management and safer more efficient patient care.
Recommendations: departments review their CI-AKI protocol,
ensure a risk assessment is performed prior to scan,
and have a mechanism to identify and manage patients who develop CI-AKI.